Tyskland underrettede den 30. maj 2006 EMEA om, at CMD( v) ikke havde kunnet nå til enighed om dette produkt.
Following discussions in the CMD(v), the proposed indication was changed during the course of the MRP to: “ For treatment of swine respiratory disease caused by susceptible Pasteurella multocida, Bordetella bronchiseptica and Mycoplasma hyopneumoniae to doxycycline. ” Germany notified the EMEA on 30 May 2006 that the CMD(v) failed to reach an agreement regarding the product.